New gene that ups Alzheimer’s risk found
Scientists, including one of Indian-origin, have have discovered an immune system gene associated with higher rates of amyloid plaque buildup.
Scientists, including one of Indian-origin, have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer’s patients and older adults at risk for the disease.
A multi-institutional team led by scientists at the Indiana University School of Medicine found that a variant in the IL1RAP gene was associated with greater amyloid plaque accumulation over two years and had an even stronger effect than the well-known APOE e4 allele which is notorious for its association with the development of Alzheimer’s disease.
Using positron emission tomography imaging in nearly 500 individuals, the researchers assessed the levels of brain amyloid deposits at an initial visit and again two years later. A genome-wide analysis was then conducted to identify genetic variants associated with the rate of plaque accumulation during this two-year window.
As predicted, APOE e4 was found to be associated with higher rates of plaque buildup. However, the investigators were surprised to find that IL1RAP, which codes for the key immune signalling factor Interleukin-1 Receptor Accessory Protein, showed an independent and even stronger influence on amyloid accumulation.
“This was an intriguing finding because IL1RAP is known to play a central role in the activity of microglia, the immune system cells that act as the brain’s “garbage disposal system” and the focus of heavy investigation in a variety of neurodegenerative diseases,” said Vijay K. Ramanan, postdoctoral researcher at the IU School of Medicine.
The new study found that the amyloid-associated IL1RAP variant was also associated with a lower level of microglial activity as measured by PET scans; greater atrophy of the temporal cortex, a region of the brain involved with memory; faster cognitive decline; and greater likelihood among study participants of progression from mild cognitive impairment to Alzheimer’s disease.
“These findings suggest that targeting the IL1RAP immune pathway may be a viable approach for promoting the clearance of amyloid deposits and fighting an important cause of progression in Alzheimer’s disease,” said Andrew Saykin, director of the Indiana Alzheimer Disease Center and the national Alzheimer’s Disease Neuroimaging Initiative Genetics Core.
Mr. Saykin noted that there are available drugs that target the IL-1/IL1RAP pathway for rheumatologic and inflammatory conditions. There are also antibodies against IL1RAP that are being tested to treat certain types of leukaemia.
Those tools could be adapted for laboratory studies to evaluate their potential as Alzheimer’s disease therapies, he said. The research was published in the journal Brain.
October 6, 2015